Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Pyloric Obstruction

Pyloric Obstruction

Pyloric obstruction, also referred to as gastric outlet obstruction, is a condition characterized by narrowing or blockage at the pylorus—the muscular valve regulating the flow of stomach contents into the duodenum. When this passage becomes impaired, the stomach cannot effectively empty its contents into the small intestine. This disruption leads to a range of gastrointestinal symptoms, including early satiety, bloating, epigastric pain, postprandial nausea, persistent vomiting, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Road Map for Opioid Management in the Inpatient Setting: A Structured Approach to Opioid Selection and Titration.

MedEdPORTAL : the journal of teaching and learning resources·2019

Same author

Sex in Nursing Homes: A Survey of Nursing Home Policies Governing Resident Sexual Activity.

Journal of the American Medical Directors Association·2015

Same author

Medical Therapy of Malignant Bowel Obstruction With Octreotide, Dexamethasone, and Metoclopramide.

The American journal of hospice & palliative care·2015

Same author

Antipsychotic drug use since the FDA black box warning: survey of nursing home policies.

Journal of the American Medical Directors Association·2011

Same author

Smoking rates in dementia patients in the outpatient setting.

Archives of gerontology and geriatrics·2010

Same author

Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole.

Neuropsychiatric disease and treatment·2010

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Adapting Human Videofluoroscopic Swallow Study Methods to Detect and Characterize Dysphagia in Murine Disease Models

Adapting Human Videofluoroscopic Swallow Study Methods to Detect and Characterize Dysphagia in Murine Disease Models

Published on: March 1, 2015

Quetiapine-associated dysphagia.

Izchak Kohen¹, Paula Lester

¹Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, NY 11004, USA. ikohen@nshs.edu

The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry

|July 11, 2008

Summary

Quetiapine, an antipsychotic, can cause dysphagia (difficulty swallowing) in elderly patients. Discontinuing the medication led to significant improvement, highlighting a potential side effect to monitor.

Related Experiment Videos

Last Updated: Jul 3, 2026

Adapting Human Videofluoroscopic Swallow Study Methods to Detect and Characterize Dysphagia in Murine Disease Models

Adapting Human Videofluoroscopic Swallow Study Methods to Detect and Characterize Dysphagia in Murine Disease Models

Published on: March 1, 2015

Area of Science:

Geriatric Medicine
Psychopharmacology
Neurology

Background:

Antipsychotic medications are frequently prescribed for conditions such as bipolar disorder.
Dysphagia is a recognized but less common side effect associated with some antipsychotics.
Geriatric populations may be more susceptible to medication-induced adverse events.

Observation:

A geriatric patient treated with quetiapine for bipolar disorder developed significant dysphagia.
The onset of dysphagia correlated with the initiation or continuation of quetiapine therapy.
Symptoms of dysphagia resolved upon discontinuation of quetiapine.

Findings:

This case suggests a causal link between quetiapine use and the development of dysphagia in an elderly patient.
Literature review indicates that antipsychotic-induced dysphagia, while rare, can occur across different drug potencies.
The mechanism may involve anticholinergic effects or direct impact on swallowing-related neural pathways.

Implications:

Clinicians should consider dysphagia as a potential adverse effect of quetiapine, particularly in geriatric patients.
Awareness of this side effect is crucial for timely diagnosis and management, potentially preventing complications like aspiration pneumonia.
Further research into the incidence and mechanisms of antipsychotic-induced dysphagia is warranted.